翻译技术速递IPO 未披露
2019-03-08微信登录
手机号登录
立即注册
手机号登录
微信登录
立即注册
注册
- 1微信扫码
- 2手机绑定
- 3完成注册
已有账号？登录
注册
- 1微信扫码
- 2手机绑定
- 3完成注册
已有账号？登录
绑定手机号
关于我们
意见反馈
$ 26.35
--(%)
04-24 17:30
Clementia Pharmaceuticals
- 并购
- 查看官网
Clementia Pharmaceuticals, Inc. provides healthcare services. It is a biopharmaceutical company, which focuses on exploiting the science of novel retinoic acid receptor gamma agonists to address bone disease and involves in development and commercialization of treatments for people living with rare diseases. Clementia Pharmaceuticals was founded by Clarissa Desjardins and Jean-Claude Tardif on November 5, 2010 and is headquartered in Montreal, Canada.
标签
医药
| 最高：-- | 今开：-- | 成交量：-- | 换手：-- |
| 最低：-- | 昨收：26.35 | 成交额：-- | 振幅：-- |
| 52周最高：26.73 | 量比：-- | 市盈率(TTM)：亏损 | 市净率：5.72 |
| 52周最低：8.10 | 委比：-87.50% | 市盈率(静)：亏损 | 市销率：-- |
| 每股收益：-1.78 | 股息：-- | 每手股数：1 | 总市值：10.04亿 |
| 每股净资产：4.61 | 股息率：-- | 最小价差：0.01 | 总股本：3810.82万 |
| 机构持股：-- | Beta：-- | 空头回补天数：0.16 | 货币单位：USD |
最新获投
最新动态
暂无数据
五力模型
暂无数据
财务指标
|
单位:美元
|
2018-06-30
|
2018-03-31
|
2017-12-31
|
2017-09-30
|
2017-06-30
|
|
流动资产
|
7,652.38万
|
6,117.31万
|
7,167.71万
|
8,248.47万
|
3,782.46万
|
|
现金及短期投资
|
6,793.72万
|
5,663.85万
|
6,623.03万
|
7,723.82万
|
3,658.42万
|
|
短期应收账款
|
267.91万
|
216.82万
|
164.79万
|
78.67万
|
50.82万
|
|
存货
|
--
|
--
|
--
|
--
|
--
|
|
其他流动资产
|
590.75万
|
236.65万
|
379.89万
|
445.99万
|
73.22万
|
|
非流动资产
|
5,164.30万
|
7,669.59万
|
7,674.83万
|
7,679.92万
|
212.55万
|
|
厂房及设备净资产
|
2.37万
|
2.84万
|
3.31万
|
3.53万
|
3.72万
|
|
项目总投资及垫款
|
5,000.00万
|
7,500.00万
|
7,500.00万
|
7,500.00万
|
--
|
|
长期应收票据
|
--
|
--
|
--
|
--
|
--
|
|
无形资产
|
161.93万
|
166.75万
|
171.52万
|
176.39万
|
181.25万
|
|
递延所得税资产
|
--
|
--
|
--
|
--
|
--
|
|
其他资产
|
--
|
--
|
--
|
--
|
27.58万
|
|
合计总资产
|
1.28亿
|
1.38亿
|
1.48亿
|
1.59亿
|
3,995.01万
|
|
流动负债
|
845.51万
|
866.17万
|
671.87万
|
649.12万
|
597.65万
|
|
短期债务（含部分LTD）
|
--
|
--
|
--
|
--
|
--
|
|
应付账款
|
--
|
--
|
--
|
--
|
--
|
|
应付所得税
|
--
|
--
|
--
|
11.99万
|
5.61万
|
|
其他流动负债
|
845.51万
|
866.17万
|
671.87万
|
637.12万
|
592.04万
|
|
非流动负债
|
0.00
|
0.00
|
0.00
|
0.00
|
2.47亿
|
|
长期负债
|
--
|
--
|
--
|
--
|
7,715.66万
|
|
拨备风险及费用
|
--
|
--
|
--
|
--
|
--
|
|
递延所得税负债
|
--
|
--
|
--
|
--
|
--
|
|
其他负债
|
--
|
--
|
--
|
--
|
1.69亿
|
|
合计总负债
|
845.51万
|
866.17万
|
671.87万
|
649.12万
|
2.53亿
|
|
股东权益合计
|
1.20亿
|
1.29亿
|
1.42亿
|
1.53亿
|
-2.13亿
|
|
非股权储备
|
--
|
--
|
--
|
--
|
--
|
|
优先股-账面价值
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
|
普通股权益（合计）
|
1.20亿
|
1.29亿
|
1.42亿
|
1.53亿
|
-2.13亿
|
|
累计少数股东权益
|
--
|
--
|
--
|
--
|
--
|
|
权益总额
|
1.20亿
|
1.29亿
|
1.42亿
|
1.53亿
|
-2.13亿
|
|
负债与股东权益合计
|
1.28亿
|
1.38亿
|
1.48亿
|
1.59亿
|
3,995.01万
|
|
每股账面价值
|
3.77
|
4.07
|
4.47
|
4.82
|
-6.97
|
|
每股账面价值-有形
|
3.72
|
4.02
|
4.41
|
4.76
|
-7.02
|
|
单位:美元
|
2018-06-30
|
2018-03-31
|
2017-12-31
|
2017-09-30
|
2017-06-30
|
|
营业总收入
|
--
|
--
|
--
|
--
|
--
|
|
-营业成本
|
5.29万
|
5.24万
|
5.41万
|
5.47万
|
5.45万
|
|
毛利
|
-5.29万
|
-5.24万
|
-5.41万
|
-5.47万
|
-5.45万
|
|
-销售管理及行政费用
|
1,128.38万
|
1,380.04万
|
1,294.59万
|
983.61万
|
867.15万
|
|
-其他运营费用
|
--
|
--
|
--
|
--
|
--
|
|
计息税前利润
|
-1,133.67万
|
-1,385.28万
|
-1,300.00万
|
-989.09万
|
-872.60万
|
|
+非经营收入(支出)
|
51.59万
|
51.58万
|
58.50万
|
30.31万
|
11.10万
|
|
-非经常性支出
|
--
|
--
|
--
|
2,900.71万
|
1,357.85万
|
|
-利息支出
|
4,567.00
|
4,276.00
|
4,018.00
|
39.59万
|
110.34万
|
|
税前净利润
|
-1,082.53万
|
-1,334.13万
|
-1,241.90万
|
-3,899.07万
|
-2,329.69万
|
|
-所得税
|
-5.77万
|
-11.01万
|
-63.00万
|
1.48万
|
2.73万
|
|
+其他税后调整
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
|
+联署公司盈利权益
|
--
|
--
|
--
|
--
|
--
|
|
合并净利润
|
-1,076.76万
|
-1,323.12万
|
-1,178.90万
|
-3,900.56万
|
-2,332.41万
|
|
-少数股东权益开支
|
--
|
--
|
--
|
--
|
--
|
|
净利润
|
-1,076.76万
|
-1,323.12万
|
-1,178.90万
|
-3,900.56万
|
-2,332.41万
|
|
-优先股股息
|
--
|
--
|
--
|
--
|
--
|
|
一般可用收入净利润
|
-1,076.76万
|
-1,323.12万
|
-1,178.90万
|
-3,900.56万
|
-2,332.41万
|
|
每股基本收益
|
-0.34
|
-0.42
|
-0.37
|
-1.83
|
-0.76
|
|
摊薄每股收益
|
-0.34
|
-0.42
|
-0.37
|
-1.83
|
-0.76
|
|
息税折旧摊销前利润
|
-1,128.38万
|
-1,380.04万
|
-1,294.59万
|
-983.61万
|
-867.15万
|
|
单位:美元
|
2017-12-31
|
2016-12-31
|
2015-12-31
|
2014-12-31
|
|
净收益
|
-1.15亿
|
-5,751.20万
|
-7,589.69万
|
-1,228.86万
|
|
+折旧损耗及摊稍
|
20.47万
|
17.26万
|
14.88万
|
13.58万
|
|
+递延税及投资税减免
|
--
|
--
|
--
|
--
|
|
+其他经营基金
|
8,221.02万
|
3,756.13万
|
5,616.45万
|
259.18万
|
|
营运资金
|
-3,304.03万
|
-1,977.81万
|
-1,958.37万
|
-956.10万
|
|
+特别项目
|
--
|
--
|
--
|
--
|
|
+营运资金变动
|
-171.21万
|
104.56万
|
206.55万
|
-7.78万
|
|
经营现金流
|
-3,475.24万
|
-1,873.26万
|
-1,751.82万
|
-963.88万
|
|
资本支出
|
-102.02万
|
-2.79万
|
-16.51万
|
-13.97万
|
|
收购所得净资产
|
--
|
--
|
--
|
--
|
|
固定资产和业务出售收入
|
--
|
--
|
--
|
--
|
|
投资买卖净额
|
-7,500.00万
|
-3,000.00万
|
--
|
--
|
|
非现金项目
|
0.00
|
0.00
|
0.00
|
0.00
|
|
投资现金流
|
-7,602.02万
|
-3,002.79万
|
-16.51万
|
-13.97万
|
|
发放现金股利
|
--
|
--
|
--
|
--
|
|
股本变动
|
1.28亿
|
--
|
5.03万
|
1.85万
|
|
发行/削减债务净额
|
987.06万
|
--
|
7,062.12万
|
1,196.89万
|
|
其他融资基金
|
--
|
--
|
--
|
--
|
|
筹资现金流
|
1.38亿
|
--
|
7,067.15万
|
1,198.73万
|
|
汇率影响
|
3.79万
|
8.81万
|
-38.52万
|
-11.96万
|
|
杂项基金
|
--
|
--
|
--
|
--
|
|
现金净流动
|
2,679.58万
|
-4,867.24万
|
5,260.29万
|
208.92万
|
|
自由现金流
|
-3,477.26万
|
-1,876.05万
|
-1,756.70万
|
-964.79万
|
公司高管
|
Francois Nader
|
Francois Nader is a businessperson who has been at the helm of 5 different companies and occupies the position of Non-Executive Chairman of Acceleron Pharma, Inc., Chief Executive Officer for Jesra Advisors LLC and President for Jesra Foundation, Inc. He is also on the board of 6 other companies.
In his past career Francois Nader held the position of Chief Medical Officer for Care Capital LLC, President, Chief Executive Officer & Director at NPS Pharmaceuticals, Inc., Head-Global Commercial Operations at Rhone-Poulenc Basic Chemical Co., Senior VP-Integrated Healthcare Markets at Hoechst Marion Roussel, Inc. and Senior VP-Integrated Healthcare Markets at Aventis Pharmaceuticals, Inc.
Francois Nader received an MBA from the University of Tennessee and a doctorate from St. Joseph University.
|
|
David M. Mott
|
|
|
Joseph Walewicz
|
Presently, Joseph Walewicz occupies the position of Investor Relations Contact at Clementia Pharmaceuticals, Inc. and Healthcare Analyst at Laurentian Bank Securities.
In his past career Mr. Walewicz was Vice President for Paladin Labs, Inc., Vice President of Equity Research at BMO Nesbitt Burns, Inc. (US), Equity Research Associate of Biotechnology at Lehman Brothers, Inc., Executive Director of Equity Research at CIBC World Markets, Inc. and Vice President & Senior Health Care Analyst at Orion Securities, Inc.
Mr. Walewicz received an MBA from McGill University and an undergraduate degree from Queen's University.
|
|
Jean-François Pariseau
|
Mr. Jean Francois Pariseau joined BDC Venture Capital in 2001. He is Partner in the Healthcare Fund.
Prior to joining BDC, he was an Investment Manager with CDP Capital Technology Ventures, and the founder-manager of 2 health care companies specializing in regulatory affairs and pharmaceutical-product distribution. He has invested in companies in the life sciences sector and actively participated in their boards of directors in both Canada and the United States since 1997.
Mr. Pariseau holds a Bachelor of Science in biotechnology from Université de Sherbrooke, a master of Science in biomedical sciences from Université de Montréal, and a M.B.A. from HEC in Montréal.
|
|
David P. Bonita
|
Dr. David P. Bonita is Independent Director at Loxo Oncology, Inc., Independent Non-Executive Director at Viewray Technologies, Inc., Private Equity Partner at OrbiMed Advisors Private Equity, Chairman at Clementia Pharmaceuticals, Inc. and Chairman at Tricida, Inc. He is on the Board of Directors at ViewRay, Inc., Loxo Oncology, Inc., Viewray Technologies, Inc., Acutus Medical, Inc., Keystone Heart Ltd. and SI-BONE, Inc.
Dr. Bonita was previously employed as Independent Director by Ambit Biosciences Corp., Finance Analyst by Morgan Stanley, and Finance Analyst by UBS Securities LLC. He also served on the board at CardiAQ Valve Technologies, Inc. and Enobia Pharma, Inc.
He received his undergraduate degree from Harvard University, an MBA from Columbia University and a doctorate degree from Columbia University.
|
|
Francois Nader
|
Francois Nader is a businessperson who has been at the helm of 5 different companies and occupies the position of Non-Executive Chairman of Acceleron Pharma, Inc., Chief Executive Officer for Jesra Advisors LLC and President for Jesra Foundation, Inc. He is also on the board of 6 other companies.
In his past career Francois Nader held the position of Chief Medical Officer for Care Capital LLC, President, Chief Executive Officer & Director at NPS Pharmaceuticals, Inc., Head-Global Commercial Operations at Rhone-Poulenc Basic Chemical Co., Senior VP-Integrated Healthcare Markets at Hoechst Marion Roussel, Inc. and Senior VP-Integrated Healthcare Markets at Aventis Pharmaceuticals, Inc.
Francois Nader received an MBA from the University of Tennessee and a doctorate from St. Joseph University.
|
|
David M. Mott
|
|
|
Joseph Walewicz
|
Presently, Joseph Walewicz occupies the position of Investor Relations Contact at Clementia Pharmaceuticals, Inc. and Healthcare Analyst at Laurentian Bank Securities.
In his past career Mr. Walewicz was Vice President for Paladin Labs, Inc., Vice President of Equity Research at BMO Nesbitt Burns, Inc. (US), Equity Research Associate of Biotechnology at Lehman Brothers, Inc., Executive Director of Equity Research at CIBC World Markets, Inc. and Vice President & Senior Health Care Analyst at Orion Securities, Inc.
Mr. Walewicz received an MBA from McGill University and an undergraduate degree from Queen's University.
|
|
Jean-François Pariseau
|
Mr. Jean Francois Pariseau joined BDC Venture Capital in 2001. He is Partner in the Healthcare Fund.
Prior to joining BDC, he was an Investment Manager with CDP Capital Technology Ventures, and the founder-manager of 2 health care companies specializing in regulatory affairs and pharmaceutical-product distribution. He has invested in companies in the life sciences sector and actively participated in their boards of directors in both Canada and the United States since 1997.
Mr. Pariseau holds a Bachelor of Science in biotechnology from Université de Sherbrooke, a master of Science in biomedical sciences from Université de Montréal, and a M.B.A. from HEC in Montréal.
|
|
David P. Bonita
|
Dr. David P. Bonita is Independent Director at Loxo Oncology, Inc., Independent Non-Executive Director at Viewray Technologies, Inc., Private Equity Partner at OrbiMed Advisors Private Equity, Chairman at Clementia Pharmaceuticals, Inc. and Chairman at Tricida, Inc. He is on the Board of Directors at ViewRay, Inc., Loxo Oncology, Inc., Viewray Technologies, Inc., Acutus Medical, Inc., Keystone Heart Ltd. and SI-BONE, Inc.
Dr. Bonita was previously employed as Independent Director by Ambit Biosciences Corp., Finance Analyst by Morgan Stanley, and Finance Analyst by UBS Securities LLC. He also served on the board at CardiAQ Valve Technologies, Inc. and Enobia Pharma, Inc.
He received his undergraduate degree from Harvard University, an MBA from Columbia University and a doctorate degree from Columbia University.
|
高管交易状态
暂无数据
持股状况
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
|---|---|---|---|---|---|
|
Sectoral Asset Management Inc
|
112213
|
0.35%
|
--
|
--
|
2018-06-30
|
|
HHG PLC
|
1746296
|
5.51%
|
-13112
|
-0.75%
|
2018-06-30
|
|
Baker Bros Advisors LP
|
1192595
|
3.76%
|
942595
|
377.04%
|
2018-06-30
|
|
Driehaus Capital Management LLC
|
823879
|
2.60%
|
-39904
|
-4.62%
|
2018-06-30
|
|
Federated Global Inv Mgmt Corp
|
678800
|
2.14%
|
--
|
--
|
2018-03-31
|
|
Janus Capital Management LLC
|
695526
|
2.19%
|
3200
|
0.46%
|
2018-06-30
|
|
J.P. Morgan Investment Management Inc
|
679361
|
2.14%
|
111553
|
19.65%
|
2018-06-30
|
|
Fidelity Management and Research Company
|
500000
|
1.58%
|
--
|
--
|
2018-06-30
|
|
Janus Capital International Ltd
|
406921
|
1.28%
|
-839
|
-0.21%
|
2018-06-30
|
|
Rock Springs Capital Management LP
|
345000
|
1.09%
|
--
|
--
|
2018-06-30
|
|
Partner Fund Management LP
|
322732
|
1.02%
|
--
|
--
|
2018-06-30
|
|
LAURION CAPITAL MANAGEMENT LP
|
228754
|
0.72%
|
228754
|
--
|
2018-03-31
|
|
Alyeska Investment Group, L.P.
|
225862
|
0.71%
|
56192
|
33.12%
|
2018-06-30
|
|
J P Morgan Asset Management (UK) Ltd
|
158536
|
0.50%
|
15921
|
11.16%
|
2018-06-30
|
|
Weiss Multi-Strategy Advisers Llc
|
153001
|
0.48%
|
-26999
|
-15.00%
|
2018-06-30
|
|
NEA Management Company, LLC
|
2141697
|
6.75%
|
--
|
--
|
2018-06-30
|
|
Wellington Management Company LLP
|
2625189
|
8.28%
|
-56498
|
-2.11%
|
2018-06-30
|
|
NEA 15 GP, LLC
|
2140246
|
6.75%
|
2140246
|
--
|
2017-12-31
|
|
BDC CAPITAL Inc
|
5497607
|
17.33%
|
5497607
|
--
|
2018-04-17
|
|
Orbimed Advisors, LLC
|
10425225
|
32.87%
|
--
|
--
|
2018-06-30
|
|
BlackRock Inc
|
354941
|
--
|
-1659
|
-0.47%
|
2018-03-31
|
|
EcoR1 Capital, LLC
|
194166
|
0.61%
|
--
|
--
|
2017-12-31
|
|
RA Capital Management, LLC
|
585403
|
1.85%
|
--
|
--
|
2017-12-31
|
|
Citadel Advisors Llc
|
122040
|
0.38%
|
--
|
--
|
2017-12-31
|
|
BlackRock Advisors LLC
|
188325
|
0.59%
|
--
|
--
|
2018-02-28
|
|
Sphera Funds Management Ltd.
|
163000
|
0.51%
|
163000
|
--
|
2017-09-30
|
|
Arrowpoint Asset Management, LLC
|
228323
|
0.72%
|
228323
|
--
|
2017-09-30
|
|
Federated Equity Mgmt Co. Of Penn
|
678800
|
2.14%
|
--
|
--
|
2017-12-31
|
|
Millennium Management LLC
|
191974
|
0.61%
|
191974
|
--
|
2017-09-30
|
|
Perceptive Advisors LLC
|
352250
|
1.17%
|
352250
|
--
|
2017-09-30
|
|
Deerfield Management Co
|
462387
|
1.46%
|
462387
|
--
|
2017-09-30
|
|
BlackRock Investment Management, LLC
|
101163
|
0.33%
|
101163
|
--
|
2017-08-31
|
|
Neuberger Berman LLC
|
100000
|
0.32%
|
100000
|
--
|
2017-09-30
|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
|---|---|---|---|---|---|
|
Weiss Alternative Balanced Risk I
|
1576
|
--
|
-1747
|
-52.57%
|
2018-06-30
|
|
Driehaus Micro Cap Growth
|
144257
|
0.45%
|
-14487
|
-9.13%
|
2018-07-31
|
|
Driehaus Event Driven
|
97332
|
0.31%
|
-62184
|
-38.98%
|
2018-07-31
|
|
Hartford Healthcare HLS IA
|
86965
|
0.27%
|
-2405
|
-2.69%
|
2018-07-31
|
|
USAA Science & Technology
|
83056
|
0.26%
|
--
|
--
|
2018-07-31
|
|
Oak Ridge Small Cap Growth A
|
41570
|
0.13%
|
41570
|
--
|
2018-05-31
|
|
JPMCB U.S. Small Cap Equity Blend Fund
|
43814
|
0.14%
|
10059
|
29.80%
|
2018-06-30
|
|
VALIC Company II Small Cap Growth
|
48721
|
0.15%
|
1253
|
2.64%
|
2018-07-31
|
|
JPMorgan Dynamic Small Cap Growth A
|
34503
|
0.11%
|
1669
|
5.08%
|
2018-07-31
|
|
Fidelity
|
21066
|
0.07%
|
--
|
--
|
2018-07-31
|
|
Federated Kaufmann II Svc
|
13800
|
0.04%
|
--
|
--
|
2018-06-30
|
|
Federated Kaufmann Small Cap A
|
125000
|
0.39%
|
--
|
--
|
2018-06-30
|
|
Hartford Healthcare A
|
392788
|
1.24%
|
-7200
|
-1.80%
|
2018-07-31
|
|
JPMorgan Small Cap Growth A
|
562123
|
1.77%
|
46129
|
8.94%
|
2018-07-31
|
|
Federated Kaufmann R
|
540000
|
1.70%
|
--
|
--
|
2018-06-30
|
|
Janus Global Life Sciences D
|
695526
|
2.19%
|
3200
|
0.46%
|
2018-06-30
|
|
Thrivent Partner Ser Healthcare A
|
3223
|
0.01%
|
-2877
|
-47.16%
|
2018-05-31
|
|
Fidelity Advisor
|
109500
|
0.35%
|
--
|
--
|
2018-06-30
|
|
BlackRock Health Sciences Opps Inv A
|
94054
|
0.30%
|
-94271
|
-50.06%
|
2018-05-31
|
|
Pacific Select Health Sciences I
|
5998
|
0.02%
|
-5976
|
-49.91%
|
2018-05-31
|
|
ALPS Medical Breakthroughs ETF
|
46117
|
0.14%
|
796
|
1.76%
|
2018-06-08
|
|
Eventide Healthcare & Life Sciences A
|
60000
|
0.19%
|
--
|
--
|
2017-12-31
|
|
RS Technology A
|
20015
|
0.06%
|
-1150
|
-5.43%
|
2017-12-31
|
|
Meridian Small Cap Growth Investor
|
125229
|
0.39%
|
125229
|
--
|
2017-09-30
|